About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Absence of Onsite Access to Specialty Pharmaceuticals Has Care and Financial Implications
Two competing hospital networks are assembling specialty pharmacy programs to satisfy drug manufacturers’ requirements for delivery of costly, restricted distribution drugs to hospitals. Hospitals’ inability to dispense such drugs can affect patient care and revenue.
Health Care & Law
Legislative and regulatory efforts to address controlled substance diversion and overuse of narcotics are affecting prescription drug utilization and patient care. These initiatives can influence formulary drug selection, prior authorization procedures, and drug utilization strategies.
E. Paul Larrat, RPh, PhD; Rita M. Marcoux, RPh, MBA; and F. Randy Vogenberg, RPh, PhD
Drugs That Offer a Survival Advantage for Men With Bone Metastases Resulting From Castration-Resistant Prostate Cancer
New and Emerging Treatment Options
A survival benefit has been demonstrated or is under investigation as the primary outcome among certain recently approved agents and investigational agents for men with metastatic castration-resistant prostate cancer that has spread to bone.
55th Annual Meeting and Exposition
Topics include pharmacological treatments for sickle-cell disease, myelofibrosis, multiple myeloma, chronic myeloid leukemia, and β-Thalassemia.
Matthew Grissinger, RPh, FaScP
American Hospital Association Wants New Concessions
FDA approvals, drug indications, and updates
Simeprevir (Olysio) for chronic hepatitis C infection; coagulation Factor XIII A-subunit (recombinant) (Tretten) for bleeding prevention in congenital Factor XIII A-subunit deficiency; and umeclidinium and vilanterol inhalation powder (Anoro Ellipta) for chronic obstructive pulmonary disease
Marvin M. Goldenberg, PhD, RPh, MS
A Novel Antisense Oligonucleotide Inhibitor for the Management of Homozygous Familial Hypercholesterolemia
Elaine Wong, PharmD, BCPS; and Tamara Goldberg, PharmD, BCPS